To determine the consequences and contexts in which eEF2K inhibition restricts cell growth, we first determined the effect of the eEF2K inhibitor TX191811 on aggressive triple breast cancer (TNBC) cell lines (BT549, Hs578t, MDA-MB-436, MDA-MB-231, MDA-MB-468) as well as the luminal breast cancer line MCF7, cultured in complete media (DMEM) supplemented with 10% fetal calf serum (FCS; Fig. 1A). Here, EEF2K is linked to breast cancer.